{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:53Z","timestamp":1707524333225},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,2]]},"DOI":"10.7759\/cureus.16128","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T02:59:22Z","timestamp":1625281162000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)"],"prefix":"10.7759","author":[{"given":"Sundar V","family":"Cherukuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Sureen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Infante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevetha","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-014-0219-0","article-title":"Primary mediastinal large B-cell lymphoma","volume":"9","author":"Dabrowska-Iwanicka A","year":"2014","unstructured":"Dabrowska-Iwanicka A, Walewski JA. Primary mediastinal large B-cell lymphoma. Curr Hematol Malig Rep. 2014, 9:273-83. 10.1007\/s11899-014-0219-0","journal-title":"Curr Hematol Malig Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy K","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, et al.. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013, 368:1408-16. 10.1056\/NEJMoa1214561","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.298","article-title":"Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies","volume":"2017","author":"Dunleavy K","year":"2017","unstructured":"Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2017, 2017:298-303. 10.1182\/asheducation-2017.1.298","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_696_16","article-title":"Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma","volume":"16","author":"Badri N","year":"2020","unstructured":"Badri N, Ngamdu KS, Torabi A, Guar S. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma. J Cancer Res Ther. 2020, 16:183-5. 10.4103\/jcrt.JCRT_696_16","journal-title":"J Cancer Res Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco C","year":"2013","unstructured":"Visco C, Tzankov A, Xu-Monette ZY, et al.. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013, 98:255-63. 10.3324\/haematol.2012.066209","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-791566","article-title":"How I treat primary mediastinal B-cell lymphoma","volume":"132","author":"Giulino-Roth L","year":"2018","unstructured":"Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood. 2018, 132:782-90. 10.1182\/blood-2018-04-791566","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2015.56388","article-title":"Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview","volume":"19","author":"Petkovi\u0107 I","year":"2015","unstructured":"Petkovi\u0107 I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn). 2015, 19:428-35. 10.5114\/wo.2015.56388","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2572","article-title":"Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16)","volume":"37","author":"Prusila RE","year":"2019","unstructured":"Prusila RE, Peroja P, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O. Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16). Hematol Oncol. 2019, 37:136-42. 10.1002\/hon.2572","journal-title":"Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.408.408","article-title":"R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines","volume":"114","author":"Moccia A","year":"2009","unstructured":"Moccia A, Schaff K, Hoskins P, et al.. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood. 2009, 114:408. 10.1182\/blood.V114.22.408.408","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30173","article-title":"Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma","volume":"122","author":"Chihara D","year":"2016","unstructured":"Chihara D, Westin JR, Oki Y, et al.. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016, 122:3145-51. 10.1002\/cncr.30173","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3179-3","article-title":"Favorable response of relapsed\/refractory gray-zone lymphoma to brentuximab vedotin","volume":"97","author":"Li J","year":"2018","unstructured":"Li J, Sim J, Leung AY, Kwong YL. Favorable response of relapsed\/refractory gray-zone lymphoma to brentuximab vedotin. Ann Hematol. 2018, 97:551-4. 10.1007\/s00277-017-3179-3","journal-title":"Ann Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda J","year":"2021","unstructured":"Svoboda J, Bair SM, Landsburg DJ, et al.. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021, 106:1705-13. 10.3324\/haematol.2019.238675","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani PL","year":"2017","unstructured":"Zinzani PL, Pellegrini C, Chiappella A, et al.. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017, 129:2328-30. 10.1182\/blood-2017-01-764258","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/48779-treatment-of-primary-mediastinal-b-cell-lymphoma-with-r-ceop-rituximab-cyclophosphamide-etoposide-vincristine-and-prednisone","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:23Z","timestamp":1707507083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/48779-treatment-of-primary-mediastinal-b-cell-lymphoma-with-r-ceop-rituximab-cyclophosphamide-etoposide-vincristine-and-prednisone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.16128","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,2]]}}}